Search Within

Neil Howard Segal

Formats
  1. Meeting Abstract (111)
  2. Journal Article (97)
  3. Review (2)
  4. Book Section (1)
  5. Miscellaneous (1)
  6. Research Letter (1)
Groups
  1. Department of Medicine (213)
  2. Gastrointestinal Oncology Service (213)
  3. Solid Tumor Oncology Division (213)
  4. Center for Pancreatic Cancer Research (98)
  5. Surgery (81)
  6. Survivorship Research (80)

More Groups

People
  1. Leonard Saltz (82)
  2. Andrea Cercek Hanjis (70)
  3. Zsofia Stadler (67)
  4. Martin Weiser (61)
  5. Rona Yaeger (61)
  6. Jinru Shia (56)

More People

Years
  1. 2025 (9)
  2. 2024 (15)
  3. 2023 (12)
  4. 2022 (14)
  5. 2021 (11)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (78)
  2. Annals of Oncology (22)
  3. Clinical Cancer Research (9)
  4. Cancer Research (6)
  5. Journal for ImmunoTherapy of Cancer (6)
  6. Modern Pathology (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (83)
  2. Oxford University Press (27)
  3. American Association for Cancer Research (21)
  4. Elsevier Inc. (19)
  5. Nature Publishing Group (10)
  6. Biomed Central Ltd (6)

More Publishers

Results (213)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Non-randomized phase II study to assess the efficacy of pembrolizumab (Pem) plus radiotherapy (RT) or ablation in mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) patients
    Meeting Abstract

    Segal, N. H.; Kemeny, N. E.; Cercek, A.; Reidy, D. L.; Raasch, P. J.; Warren, P.; Hrabovsky, A. E.; Campbell, N.; Shia, J.; Goodman, K. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Safety and efficacy of durvalumab (MEDI4736) a PD-L1 antibody, in urothelial bladder cancer
    Meeting Abstract

    Massard, C.; Gordon, M. S.; Sharma, S.; Rafii, S.; Wainberg, Z. A.; Luke, J. J.; Curiel, T. J.; Colon-Otero, G.; Hamid, O.; Sanborn, R. E.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Somatic tumor profiling of DNA mismatch repair deficient (MMR-D) colorectal cancers (CRC)
    Meeting Abstract

    Ganesh, K.; Middha, S.; Hechtman, J. F.; Ashraf, A.; Tran, C.; Villano, D.; Yaeger, R. D.; Segal, N. H.; Cercek, A.; Varghese, A. M.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naive patients with advanced non small-cell lung cancer
    Meeting Abstract

    Antonia, S. J.; Kim, S. W.; Spira, A. I.; Ahn, M. J.; Ou, S. H. I.; Stjepanovic, N.; Fasolo, A.; Jager, D.; Ott, P. A.; Wainberg, Z. A.; more...
    Journal of Clinical Oncology (2016)

    Fulltext@MSK | Save
  • Assessing the potential for enhanced antibody-dependent cellmediated cytotoxicity (ADCC) by combining the CD137 antibody urelumab with rituximab or cetuximab in patients with refractory lymphoma or select advanced solid tumors
    Meeting Abstract

    Segal, N. H.; Sharma, M.; Le, D. T.; Ott, P. A.; Ferris, R. L.; Zelenetz, A. D.; Neelapu, S. S.; Levy, R.; Lossos, I. S.; Jacobson, C.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Clinical safety and efficacy assessment of the CD137 agonist urelumab alone and in combination with nivolumab in patients with hematologic and solid tumor malignancies
    Meeting Abstract

    Massarelli, E.; Segal, N. H.; Ribrag, V.; Melero, I.; Gangadhar, T. C.; Urba, W.; Schadendorf, D.; Ferris, R. L.; Houot, R.; Morschhauser, F.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Preliminary efficacy from a phase I/II study of the natural killer cell–targeted antibody lirilumab in combination with nivolumab in squamous cell carcinoma of the head and neck
    Meeting Abstract

    Leidner, R.; Kang, H.; Haddad, R.; Segal, N. H.; Wirth, L. J.; Ferris, R. L.; Hodi, F. S.; Sanborn, R. E.; Gajewski, T. F.; Sharfman, W.; more...
    Journal for ImmunoTherapy of Cancer (2016)

    Fulltext@MSK | Save
  • Safety of the natural killer (NK) cell-targeted anti-KIR antibody, lirilumab (liri), in combination with nivolumab (nivo) or ipilimumab (ipi) in two phase 1 studies in advanced refractory solid tumors
    Meeting Abstract

    Segal, N. H.; Infante, J. R.; Sanborn, R. E.; Gibney, G. T.; Lawrence, D. P.; Rizvi, N.; Leidner, R.; Gajewski, T. F.; Bertino, E.; Sharfman, W. H.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort
    Meeting Abstract

    Segal, N. H.; Ou, S. H. I.; Balmanoukian, A. S.; Massarelli, E.; Brahmer, J. R.; Weiss, J.; Schoffski, P.; Antonia, S. J.; Massard, C.; Zandberg, D. P.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Antonia, S. J.; Brahmer, J. R.; Khleif, S.; Balmanoukian, A. S.; Ou, S. H. I.; Gutierrez, M.; Kim, D. W.; Kim, S. W.; Ahn, M. J.; Leach, J.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save